POSITRON

Originally a research and development company focused on technology, Positron’s business strategy has evolved over the past 3 years from an imaging device manufacturer to a company that provides a comprehensive “full nuclear cardiology solution”. Positron is actively pursuing key initiatives to ensure the growth and longevity of the company, as well as, the industry by securing the supply of key isotopes, providing necessary radiopharmaceuticals that apply to both PET and SPECT imaging modalities and offering attractive financing solutions. We strive to maximize market share by offering cost-effective, value added solutions to end-users, with the objective of becoming a sustained long-term value creator for industry participants and shareholders.